FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  2. Everlaan Organics, Inc. dba Maple Organics

    FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.

    High risk
  3. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  4. Biomic Sciences, LLC dba ION Intelligence of Nature

    Biomic Sciences' nasal spray was grossly contaminated with microorganisms, and FDA also found manufacturing and labeling violations.

    High risk
  5. Inmar Supply Chain Solutions, LLC

    FDA found severe rodent infestation at Inmar warehouse, adulterating stored foods, over-the-counter drugs, and devices.

    High risk
  6. Green Pharmaceutical Co. Ltd.

    FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.

    High risk
  7. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  8. Aspire Pharmaceuticals, Inc.

    FDA warning letter to Aspire Pharmaceuticals cites dietary supplement and drug CGMP violations, including falsified lab data and missing impurity testing.

    High risk
  9. Vitae Enim Vitae Scientific Inc.

    FDA warned Vitae Enim Vitae Scientific of sterile drug CGMP violations and contamination-control failures after a 2021 inspection, leading to a recall.

    High risk